NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC

Exclusion Criteria

• •1. Pregnant or lactating women.
• •2. Researchers believe that any condition that may pose a risk to receiving study treatment or interfere with the evaluation of study treatment, subject safety, or interpretation of study results.
• •3. Previously received treatment with EGFR antagonists or ALK antagonists.
• •4. Previously participated in experimental drug studies or received research treatment or used experimental devices within 4 weeks prior to the first administration.
• •5. Simultaneously enrolled in another clinical study, unless it is an observational, non interventional clinical study or an interventional study with a follow-up period (defined as the time from the first administration to the last administration of the previous clinical study being more than 4 weeks or the study drug having more than 5 half lives).
• •6. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• •7. Suffering from active, known or suspected autoimmune diseases, or having a history of autoimmune diseases, except for vitiligo, hair loss, Graves' disease, psoriasis or eczema that do not require systemic treatment within the past 2 years, hypothyroidism (caused by autoimmune thyroiditis) that only requires stable doses of hormone replacement therapy, and type I that only requires stable doses of insulin replacement therapy, diabetes or childhood asthma that have completely alleviated without any intervention after adulthood, or whose disease will not recur without external triggers.
• •8. Active or previously recorded inflammatory bowel disease (such as Crohn's disease, ulcerative colitis, or chronic diarrhea).
• •9. Subjects who require systemic treatment with corticosteroids (\>10 mg/day prednisone equivalent dose) or other immunosuppressive drugs within 14 days prior to the first administration. Except for the following: a) If there is no active autoimmune disease, inhaled, ophthalmic, or topical corticosteroids and corticosteroids at doses not exceeding 10mg/day effective dose of prednisone are allowed for treatment. b) The dosage of systemic corticosteroids at physiological doses does not exceed 10 mg/day of prednisone or equivalent doses of other corticosteroids. c) Corticosteroids are used as preventive medication for hypersensitivity reactions (such as medication before CT examination).
• •10. Known history of primary immunodeficiency virus infection.
• •11. Suffering from other active malignant tumors within the first 5 years of enrollment. Locally curable cancers (manifested as cured) are excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.
• •12. Having undergone major surgical procedures (defined by the investigator, such as open biopsy, severe trauma, etc.) within 28 days prior to the first administration. Note: For the replacement of intravenous drip tubes, it is acceptable. Within 30 days after the first administration (as determined by the researcher), there are significant surgical plans or complete recovery from previous surgeries. Local surgeries (such as placement of systemic ports, hollow core needle biopsy, and prostate biopsy) are allowed, provided that the surgery is completed at least 24 hours before the first administration of the investigational therapeutic drug.
• •13. Subjects who have not recovered from the toxicity and/or complications of previous interventions to NCI-CTC AE ≤ 1 degree (excluding hair loss and fatigue) prior to their first medication.
• •14. History of gastrointestinal perforation and/or fistula within 6 months prior to initial administration.
• •15. Known history of interstitial lung disease. Exclude subjects highly suspected of having interstitial pneumonia; Or subjects who may interfere with the detection or treatment of suspected drug-related pulmonary toxicity; Or other moderate to severe lung diseases that seriously affect lung function.
• •16. Known history of active pulmonary tuberculosis (TB). Subjects suspected of having active TB should undergo chest X-ray, sputum examination, and exclusion based on clinical symptoms and signs.
• •17. Severe infection occurred within 4 weeks prior to the first administration, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia.
• •18. Active infections that require systemic treatment.
• •19. Untreated chronic hepatitis B patients or HBV carriers with chronic hepatitis B virus (HBV) DNA exceeding 500 IU/mL, or active hepatitis C patients should be excluded. Non active HBsAg carriers, treated and stable hepatitis B patients (HBV DNA\<500 IU/mL), and cured hepatitis C patients can be enrolled. For HCV antibody positive subjects, they are only eligible to participate in the study if their HCV RNA test results are negative.
• •20. Individuals who test positive for HIV.
• •21. Any of the following cardiovascular diseases: a) Evidence of acute or sustained myocardial ischemia; b) Current symptomatic pulmonary embolism; c) Acute myocardial infarction within the first 6 months of randomization; d) Symptomatic congestive heart failure (grade 3 or 4 according to the New York Heart Association functional classification) within the first 6 months of randomization; e) Grade 2 or above ventricular arrhythmia within the first 6 months of randomization; f) Cerebrovascular accident (CVA) or transient ischemic attack within the first 6 months of randomization.
• •22. Those who have received a live or attenuated vaccine within 30 days prior to the first dose, or those who plan to receive the vaccine during the study period.
• •23. Known history of severe hypersensitivity reactions to other monoclonal antibodies.